Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Lignende værker

• Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
  af: Wester, Ruth, et al.
  Udgivet: (2019)
• Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
  af: Sonneveld, Pieter, et al.
  Udgivet: (2015)
• Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology
  af: Hazenberg, Bouke P.C., et al.
  Udgivet: (2015)
• Treatment of relapsed and refractory multiple myeloma
  af: Sonneveld, Pieter, et al.
  Udgivet: (2016)
• Treatment of relapsed and refractory multiple myeloma
  af: Sonneveld, Pieter, et al.
  Udgivet: (2016)